NFC
HRMY icon

Northeast Financial Consultants’s Harmony Biosciences HRMY Stock Holding History

Northeast Financial Consultants’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,629
Closed -$255K – 323
2022
Q4 		$255K Sell
4,629
-4,500
-49% -$247K 0.02% 262
2022
Q3 		$404K Sell
9,129
-9,000
-50% -$439K 0.03% 219
2022
Q2 		$884K Hold
18,129
– – 0.06% 144
2022
Q1 		$882K Hold
18,129
– – 0.05% 169
2021
Q4 		$773K Sell
18,129
-18,000
-50% -$717K 0.05% 180
2021
Q3 		$1.39M Buy
36,129
+746
+2% +$24K 0.09% 126
2021
Q2 		$999K Buy
+35,383
New +$1.06M 0.07% 160

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northeast Financial Consultants's HRMY Position: Q1 2023 in Review

Northeast Financial Consultants sold out of Harmony Biosciences (HRMY) in Q1 2023, closing a stake of 4,629 shares — an estimated $255K sold.

Northeast Financial Consultants first reported a position in HRMY in Q2 2021 and held it in 7 quarters. The position peaked at $1.39M in Q3 2021. 217 funds tracked by Wall St. Rank hold HRMY as of Q1 2023.

  • Northeast Financial Consultants reported no remaining Harmony Biosciences position as of Q1 2023 after selling out during the quarter.
  • Northeast Financial Consultants sold 4,629 Harmony Biosciences shares in Q1 2023, an estimated $255K.
  • Northeast Financial Consultants first reported a position in Harmony Biosciences in Q2 2021 and held it in 7 quarters.
  • Northeast Financial Consultants's Harmony Biosciences position peaked at $1.39M in Q3 2021.
  • 217 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2023.

Based on Northeast Financial Consultants's 13F filing for Q1 2023, filed 15 May 2023.